Frazier Life Sciences Management, L.P. Krystal Biotech, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 988,460 shares of KRYS stock, worth $157 Million. This represents 9.67% of its overall portfolio holdings.
Number of Shares
988,460
Previous 988,460
-0.0%
Holding current value
$157 Million
Previous $182 Million
0.97%
% of portfolio
9.67%
Previous 10.7%
Shares
7 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$629 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$454 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$418 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$231 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA879KShares$140 Million0.03% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.09B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...